Table 4.

Categorical Baseline Measures by POAG Outcome for OHTS Observation Group and EGPS Placebo Group

	Study Group								OHTS and EGPS Control Groups
	OHTS Observation				EGPS Placebo
	Developed POAG				Developed POAG				Developed POAG
	No		Yes		No		Yes		No		Yes
	N	%	N	%	N	%	N	%	N	%	N	%
Race
Native American	1	50.0	1	50.0	0	0	0	0	1	50.0	1	50.0
Asian Pacific Islander	0	0	0	0	0	0	0	0	0	0	0	0
Black, Non Hispanic	168	83.6	33	16.4	0	0	0	0	168	83.6	33	16.4
Hispanic	26	76.5	8	23.5	0	0	0	0	26	76.5	8	23.5
White, Non Hispanic	499	89.3	60	10.7	439	87.8	61	12.2	938	88.6	121	11.4
Other	5	83.3	1	16.7	0	0	0	0	5	83.3	1	16.7
Gender
Female	419	89.3	50	10.7	224	86.5	35	13.5	643	88.3	85	11.7
Male	289	84.3	54	15.7	215	89.2	26	10.8	504	86.3	80	13.7
Either eye myopia worse than -1D
No	460	87.3	67	12.7	359	87.8	50	12.2	819	87.5	117	12.5
Yes	248	87.0	37	13.0	80	87.9	11	12.1	328	87.2	48	12.8
Self-reported medical history at baseline
Calcium channel blockers
No	617	87.1	91	12.9	418	88.0	57	12.0	1035	87.5	148	12.5
Yes	88	87.1	13	12.9	21	84.0	4	16.0	109	86.5	17	13.5
Beta blockers
No	674	86.9	102	13.1	410	88.2	55	11.8	1084	87.3	157	12.7
Yes	31	93.9	2	6.1	29	82.9	6	17.1	60	88.2	8	11.8
Diabetes
No	613	86.0	100	14.0	414	87.3	60	12.7	1027	86.5	160	13.5
Yes	95	96.0	4	4.0	25	96.2	1	3.8	120	96.0	5	4.0
History of heart disease
No	665	87.7	93	12.3	392	88.1	53	11.9	1057	87.9	146	12.1
Yes	43	79.6	11	20.4	47	85.5	8	14.5	90	82.6	19	17.4
History systemic hypertension
No	442	87.7	62	12.3	316	88.5	41	11.5	758	88.0	103	12.0
Yes	266	86.4	42	13.6	123	86.0	20	14.0	389	86.3	62	13.7
History of Migraine
No	626	87.3	91	12.7	439	87.8	61	12.2	1065	87.5	152	12.5
Yes	82	86.3	13	13.7	0	0	0	0	82	86.3	13	13.7
Stroke
No	697	87.2	102	12.8	438	87.8	61	12.2	1135	87.4	163	12.6
Yes	11	84.6	2	15.4	1	100.0	0	0	12	85.7	2	14.3

D Diopter

EGPS European Glaucoma Prevention Study

OHTS Ocular Hypertension Treatment Study

POAG Primary open angle glaucoma